Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/04—Macromolecular materials
  • A61L31/043—Proteins; Polypeptides; Degradation products thereof
  • A61L31/044—Collagen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/02—Prostheses implantable into the body
  • A61F2/30—Joints
  • A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/02—Prostheses implantable into the body
  • A61F2/30—Joints
  • A61F2/30756—Cartilage endoprostheses
  • A61F2002/30757—Cartilage endoprostheses made of a sheet covering the natural articular surface, e.g. cap
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/02—Prostheses implantable into the body
  • A61F2/30—Joints
  • A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
  • A61F2/442—Intervertebral or spinal discs, e.g. resilient
  • A61F2002/4445—Means for culturing intervertebral disc tissue
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
  • A61F2310/00005—The prosthesis being constructed from a particular material
  • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof

Definitions

• the present invention relates to a method for preventing post-surgical or posttraumatic cellular adhesion on the surface of a tissue selected from spinal column tissue, dura mater and spinal nerves comprising the step of covering and separating the tissue with a multilayered bioactive and biofunctional collagen biomatrix foil, and to a method of directing cell growth and tissue repair and for treating a disorder in a mammal comprising the step of covering and separating said tissue with a multilayered collagen foil biomatrix.
• the methods of the present invention prevent peridural and perineural adhesion and scar tissue formation by providing a biofunctional matrix for directed ingrowth of cells and controlled tissue regeneration.
• anti-adhesion gels have limited success as a barrier and have undefined layer thickness. These anti-adhesion gels have low hemostatic properties, if any at all, and provide no wound healing support functions and do not direct cell growth and tissue regeneration. There are even reports of increased rates of CSF (cerebro spinal fluid) leaks accruing in conjunction with the use of ADCON-L (Hieb, L. D. & Stevens, D. L. (2001). Spontaneous postoperative cerebrospinal fluid leaks following application of anti- adhesion barrier gel: case report and review of the literature. Spine, 26(7), 748-751.; Kuhn, J., Hofmann, B., Knitelius, H. O., Coenen, H.
• DURAGEN PLUS One commercially available anti-adhesion product is DURAGEN PLUS.
• the DURAGEN PLUS barrier which is of bovine origin, is not very shape stable, which means that its shape and position is difficult to correct after application. Further, the DURAGEN PLUS barrier does not have a high tensile strength and elasticity. And due to the fact that the DURAGEN PLUS barrier is porous it is consequently not fluid-tight (impermeable to fluids) and therefore has limited success as a barrier function.
• DURAGEN PLUS absorbs blood which can results in fibrin bands that play a key role in the pathogenesis of adhesion formations and its porous structure promotes non-directed cell in-growth which may also contribute to uncontrolled fibrotic tissue formation and to adhesions.
• the present invention is directed to compositions and methods of preventing post-surgical or post-traumatic peridural or perineural adhesion and fibrosis formation, directing cell growth and cell in-growth and controlling tissue regeneration after surgery or trauma by using a multilayer collagen foil biomatrix to cover and separate tissues such as spinal column tissues.
• Spinal column tissues include those such as spinal canal tissues, dura mater and spinal nerves.
• the methods of the present invention may be used, for example, during spinal surgery, in a mammal, e.g., a human being, comprising the step of covering and separating the tissue with a microscopically multilayered collagen foil biomatrix.
• the multilayered collagen foil biomatrix attracts cells selected from the group consisting of repair cells and regeneration cells.
• the multilayered structure of the biofunctional collagen foil biomatrix directs the cell growth on to the surface, and the in-growth of cells such as repair cells and regeneration cells and is remodeled to natural tissue after said in-growth and is resorbed.
• the present invention relates to a method for treating a disorder in a mammal characterized by a defect of the spinal column tissue, comprising the step of covering and separating said tissue and/or a surrounding tissue with a multilayered collagen foil biomatrix in order to inhibit uncontrolled tissue formation.
• the multilayered collagen foil biomatrix of the present invention acts as a membrane (e.g., spinal membrane) functioning as a bioactive temporary separation layer directing cell growth within the multilayered collagen foil biomatrix and on the surface of the collagen foil biomatrix.
• the multilayered collagen foil biomatrix of the present invention is extremely bioactive and supports the remodeling of the tissues. For example, two weeks after implantation, the multilayered collagen foil biomatrix of the present invention is already well integrated into the restored anatomical structure of peridural tissues.
• the nonporous, fluid-tight (e.g., blood) multilayered structure of the collagen membrane of the present invention is capable of preventing uncontrolled distribution of blood (e.g., fibrinogen /fibrin) and necrotic material from the peridural wound areas, which are responsible for supporting conditions of adhesion formation in the initial time period after surgery (in contrast to porous compositions).
• the collagen biomatrix of the present invention also prevents direct contact between the dura mater and the peridural wound area, the primary area of the scar formation and fibrosis. This contributes also to the controlled remodeling of anatomical structures with prevention and minimization of uncontrolled adhesion and scar formation and peridural fibrosis.
• the present invention is directed in part to the following:
• a method for directing cell growth and controlled tissue regeneration and preventing post-surgical or post-traumatic adhesion and fibrosis formation on the surface of a tissue in a mammal comprising the steps of providing, covering and separating the tissue with a non-porous microscopically multilayered collagen foil biomatrix.
• tissues are selected from the group consisting of spinal column tissue, dura mater and spinal nerves.
• the collagen foil is derived from one of the following sources selected from the group consisting of bovine, porcine, equine, or human collagen and mixtures thereof and is attached to the tissues of the mammal using a fibrin sealant.
• a method of preventing adhesions in mammals comprising the steps of providing, covering and separating tissue with a biofunctional, non-porous multilayered collagen foil biomatrix wherein the multilayered collagen foil has interstices between the layers for directing cell growth within and on the multilayered collagen foil biomatrix.
• tissue is selected from the group consisting of spinal column tissue, dura mater, and spinal nerves.
• a composition for use in adhesion prevention and prevention of fibrosis formation comprising a microscopically multilayered collagen foil biomatrix wherein the multilayered collagen foil directs the growth of cells in the interstices between the collagen layers and on the outer surface of the multilayered collagen foil biomatrix.
• composition of paragraph 23 wherein the multilayered collagen foil biomatrix is derived from materials selected from the group consisting of bovine, porcine, equine, or human collagens.
• composition of paragraph 23 wherein the multilayered collagen foil biomatrix is derived from equine collagen.
• composition in the manufacture of a medicament for the prevention of adhesions and prevention of fibrosis formation in a mammal
• the composition consists of a microscopically multilayered collagen foil biomatrix wherein the multilayered collagen foil directs the growth of repair and/or regeneration cells in the interstices between the collagen layers wherein the collagen is selected from one of the group consisting of bovine, porcine, equine, or human collagen and mixtures thereof.
• Fig. 1 is a SEM (scanning electron microscope) photograph illustrating the surface of a biofunctional collagen foil biomatrix. Collagen fibrils are clearly illustrated. Substantial non-porosity of the surface is evident from the picture;
• FIGs. 2A and 2B are photographs taken under ESEM (environmental scanning electron microscopy) conditions, which means near natural conditions in a slightly humid atmosphere, illustrating the upper surface, seen from the side of a biofunctional collagen foil biomatrix. Substantial non-porosity is evident from the photographs;
• FIGs. 3A and 3B are photographs taken under ESEM conditions illustrating the lower surface of a biofunctional collagen foil biomatrix. Collagen fibrils are illustrated in Fig 3A. Substantial non-porosity of the surface is evident from the pictures;
• Fig. 4 is a SEM photograph illustrating the surface of a hydrated biofunctional collagen foil biomatrix. Collagen fibrils are clearly illustrated in Fig. 4. Substantial non- porosity of the surface is evident from the picture;
• FIGs. 5A, 5B, and 5C are photographs taken under ESEM conditions (humid atmosphere) illustrating the cross section of a biofunctional collagen foil biomatrix. The material reveals a structure like a stack of sheets packed very tightly together. Interstices between the collagen layers are shown in the picture;
• Figs. 6A and 6B are SEM photographs illustrating the cross section of a dry biofunctional collagen foil biomatrix. Multiple layers of collagen and interstices between the collagen layers are illustrated in the pictures;
• FIG. 7 is an illustration of one embodiment of the invention, in which the biofunctional collagen foil biomatrix is placed over the edges of a surgically produced defect in the vertebra, and on top of the dura mater, in order to direct cell in-growth and control tissue regeneration, thus preventing adhesion of the regenerating wound tissue to the spinal dura mater and spinal nerves.
• the edges of the biofunctional collagen foil biomatrix are secured to the lateral exterior wound surface of the vertebra;
• FIG. 8 is an illustration of another embodiment of the invention, in which the biofunctional collagen foil biomatrix is placed under a surgically produced defect in the vertebra, and on top of the dura mater, in order to prevent adhesion of the regenerating wound tissue to the spinal dura mater and spinal nerves.
• the edges of the biofunctional collagen foil biomatrix are secured to the interior surface of the vertebra, in the spinal canal;
• Fig. 9 is a sectional view of the collagen foil biomatrix one week postoperatively.
• the structure of the surface is non-porous and forms a temporary barrier. Blood (erythrocytes) are separated and did not penetrate into the multi-layered collagen foil biomatrix;
• Fig. 10 shows the collagen foil biomatrix one week after implantation.
• the human patient (age: 18, gender: female) was operated in the interval of 7 days in the frame of a routine surgical treatment (epilepsy).
• the collagen foil biomatrix was implanted epidural during the first surgery (prevention of CSF leaks).
• the collagen foil biomatrix implant was removed routinely before the reopening of the dura.
• the collagen foil biomatrix is still mechanically stable and removable.;
• Fig. 11 is a sectional view of the collagen foil biomatrix rim one week after implantation. Fibroblasts have invaded the biomatrix to about 25 ⁇ m from the lower side and are spreading in a directed longitudinal in-growth along the parallel multi-layered structures and are growing into the collagen foil biomatrix, directed by the multi-layer structure.
• the penetration in longitudinal direction is about 220 to 320 ⁇ m.
• the speed of the directed in-growth of repair cells along the multi-layered structure is about 10 to 15 times higher in longitudinal direction compared to the transversal direction ("Fig. 10").
• Fig. 12 shows postoperative slides of a New Zealand white (“NZW") rabbit with magnification x 20 with HE staining as taught in Example I.
• the multilayered collagen foil biomatrix is a separation layer between the dura mater and the dorsal wound area and provides a bioactive multilayer structure which is nonporous and fluid-tight to blood;
• Fig. 13 A shows a NZW rabbit 1 week postoperative; Magnification: x 2,5; HE staining.
• the multilayered collagen foil biomatrix is closing the laminectomy defect and separating the epidural space from the beginning cell rich dorsal scar formation;
• Fig. 13 B shows a NZW rabbit 1 week postoperative; Magnification: x20, HE staining. The figure shows the contact area between the multilayered collagen foil biomatrix and the bone at the edge of the defect (a);
• FIG. 13 C shows a rabbit 1 week postoperative; Magnification: x 20; HE staining.
• the multilayered collagen foil biomatrix is in the center of the laminectomy defect.
• the multilayered collagen foil biomatrix is integrated and is separating the ventral epidural space from the dorsal scar formation;
• FIG. 13 D shows a NZW rabbit 1 week postoperative; Magnification: x 2,5; HE staining.
• the multilayered collagen foil biomatrix is closing the laminectomy defect and separating the dura from the beginning cell rich dorsal scar formation. Cells have not penetrated the surface of the collagen biomatrix. At the edge of the collagen biomatrix beginning directed infiltration of repair cells into the multilayer structure(a);
• Fig. 13 E shows a NZW rabbit 1 week postoperative; Magnification: x 2,5; HE staining.
• a collagen sponge (DURAGEN) was used to cover the laminectomy defect. No clear non-porous separation layer between the epidural space and the dorsal wound area. The sponge is soaked with blood;
• Fig. 14 A shows a rabbit two weeks postoperative; Magnification: x 2,5; HE staining.
• the multilayered collagen foil biomatrix is fully integrated. Tissue repair cells have infiltrated the collagen biomatrix and the dura mater is separated by loose tissue with fat cells from the scar formation and the remodeled collagen biomatrix;
• Fig. 14 B shows a rabbit two weeks postoperative; Magnification: x 4; HE staining; the multilayered collagen foil biomatrix is fully integrated. Tissue repair cells have infiltrated the multilayer structure of the collagen biomatrix. The dura mater is separated by loose tissue with fat cells from the scar formation and the remodeled collagen biomatrix; and,
• Fig. 14 C shows a rabbit two weeks postoperative; Magnification: x 10; HE staining; the multilayered collagen foil biomatrix is fully integrated. Tissue repair cells have infiltrated the multilayer structure of the collagen biomatrix (a). The dura mater is separated by loose tissue with fat cells from the scar formation and the remodeled collagen biomatrix.
• One aspect of the present invention relates to a method for preventing postsurgical or post-traumatic peridural or perineural adhesion and fibrosis formation on the surface of spinal column tissue, including tissues selected from the group consisting of spinal canal tissues, dura mater, and spinal nerves in a mammal, comprising the step of covering the tissue and separating the tissue from other surrounding tissues with a microscopically multilayered collagen foil biomatrix.
• the multilayered collagen foil biomatrix according to the present invention is a collagenous native cross-linked microscopically multilayered biomatrix consisting of multiple layers of a substantially non-porous foil comprised of collagen fibrils in a non- naturally occurring biomatrix, e.g., as described in the international patent application WO 04/108179, the disclosure of which is herewith incorporated by reference in its entirety.
• the collagen foil used according to the present invention is biofunctional, bioactive, mechanically stable, elastic, non-porous and fluid-tight, especially blood and cell tight, temporary barrier against uncontrolled distribution of blood, fibrinogen, necrotic material and damaged tissues.
• a defined bioactive separation layer between the spinal column tissues thus initially shields the spinal column tissue and surrounding tissues, one or both of which may be abraded or otherwise damaged.
• the multilayered collagen foil biomatrix acts as hemostatic agent and inhibits uncontrolled fibrin bands formation and distribution as well as hematomas, which are one of the main causes for fibrosis and adhesion formation, in anatomical areas which are located beside or close to the dura mater or spinal nerves.
• the cells whose adhesion to the spinal nerves and/or the dura mater is prevented by the method according to the present invention are selected from connective tissue cells.
• the mammal may be any mammal, such as humans, mice, rats, cats, dogs, etc.
• the step of covering and separating the tissue with a multilayered biofunctional collagen foil biomatrix may be carried out during the treatment of any injuries or defects of the spinal dura mater or the spinal column.
• the step of covering and separating the tissue with a multilayered collagen foil biomatrix may be carried out during spinal surgery.
• the multilayered collagen foil biomatrix attracts cells such as repair cells and regeneration cells and directs their ingrowth through and on the foil biomatrix.
• the multilayered collagen foil biomatrix is reabsorbed and remodeled to natural tissue by the in-growth of cells.
• the collagen foil biomatrix acts as a bioactive and biofunctional scaffold for cellular in-growth in vivo and is replaced by mammalian tissue during regeneration and restoration.
• the collagen foil biomatrix is resorbable by the mammal in which it is implanted. This property may be enhanced by the biofunctionality of the native cross-linked collagen fibers and the multilayered structure of the collagen foil biomatrix, as shown in Figures 5 - 6.
• the process utilized to produce the collagen foil biomatrix used in the invention forms stacked layers of collagen fibrils. Between each layer are interstices into which cells and vasculature of the patient can migrate and form new collagen structures and native-conformation tissue. It is a beneficial property of the method according to the present invention that the biofunctional native collagen fibers and the non-porous, layered structure of the collagen foil biomatrix promotes the in-growth of cells, vasculature, and the formation of new collagen structures across the collagen foil biomatrix and in the interstices that exist between its multiple layers.
• the directed in-growth and regeneration in the methods of the invention prevents the formation of adhesions and fibrosis, maintaining the separation of the tissues in the spinal column anatomical structure.
• pain and complications associated with peridural or perineural adhesions and fibrosis are avoided.
• the phrase "covering the tissue with a multilayered collagen foil biomatrix” means, in general, bringing the tissue into physical contact with a multilayered collagen foil biomatrix.
• the contacting of the tissue with a multilayered collagen foil biomatrix results in an implantation of said foil. Examples of the positioning of the multilayered collagen foil biomatrix are illustrated in Figures 7 - 8.
• multilayered collagen foil biomatrix or "collagen biomatrix” or “collagen foil” as used herein means a biomatrix (i.e. a matrix of biocompatible and biofunctional material) of native collagen fibrils treated to remove non-collagenous components and to form a sheet of collagen fibrils with a multilayered laminar structure on a microscopic level.
• the multilayered collagen foil may be from any source, such as bovine, ovine, porcine, equine, or human origin treated to remove non-collagenous components and to form a sheet of collagen fibrils, with the same physical characteristics.
• the collagen foil biomatrix of the present invention is substantially non- porous, as determinable by scanning electron microscopy.
• biofunctional as used herein in the context of a biofunctional multilayered foil biomatrix means that the biomatrix consists of native collagen fibrils that are recognized and utilized by the cells of an animal in a manner similar to the native collagen fibrils in the animal.
• functions may include migration of repair and regeneration cells along the biofunctional collagen fibrils and the multi-layered structure, and the deposition of new extracellular matrix by the cells including, or replacing, the biofunctional collagen fibrils.
• non-naturally occurring biomatrix means a manufactured matrix or framework comprising native collagen fibrils formed from (i) a material existing in nature (i.e. natural material) that has been treated or processed in a manner in which the collagen fibrils contained in the natural material have been moved or repositioned from their naturally-occurring arrangement within the collagen structure of the natural material; or (ii) a material not existing in nature (i.e. a non-natural, artificial material, such as a recombinant material) treated or processed to manipulate the arrangement of the collagen fibrils.
• a non-naturally occurring biomatrix may be formed from starting material comprising collagen that has been mechanically or chemically processed (e.g.
• a collagen biomatrix that is formed from the treatment or processing of starting material in a manner that preserves the structure of the naturally occurring collagen framework is not a non-naturally occurring biomatrix (e.g. epidermal tissue treated to remove cellular components while preserving the naturally occurring collagen structure).
• the collagen foil biomatrix is comprised of connective tissue proteins consisting of collagen fibrils.
• the collagen foil biomatrix may be comprised of connective tissue proteins consisting of Type I collagen fibrils.
• the collagen foil biomatrix can further comprise an excipient, a preservative, a growth factor, or an additive that aids in the flexibility and elasticity of the final product.
• Each layer of collagen fibrils is substantially non-porous.
• substantially non-porous means that any pores that are present in a collagen foil biomatrix as a result of precipitation of collagen fibrils to form a collagen sheet are primarily isolated from one another. The pores are not interconnected in a manner that traverses the thickness of the collagen foil. Mechanical perforations that create holes in the collagen foil biomatrix are not pores. In one example of the present invention the material appears to be substantially free of pores that would be visible using a scanning electron microscope at 150Ox magnification. Scanning electron microscope pictures illustrate the non-porous nature of the collagen foil biomatrix as in Figures 1 - 4.
• the collagen foil biomatrix utilized in the present invention is a non-naturally occurring multi-layered collagen membrane consisting of layers of numerous multi-directional intertwined collagen fibrils.
• the collagen fibrils are arranged in a multi-directional fashion in a plane, and these planes form sheets, which create a multi-layered structure.
• An illustration of a dry collagen foil biomatrix may be seen in a photomicrograph (SEM) 1 which illustrates the surface of the collagen foil biomatrix in which collagen fibrils are embedded ( Figure 1 ).
• the collagen fibrils are visible on the surface on photographs of the upper surface of the collagen foil biomatrix under ESEM (Environmental Scanning Electron Microscopy) conditions, in which a slightly humid atmosphere provides near natural conditions.
• the surface appears smooth and substantially non-porous ( Figure 2).
• Photographs (ESEM) of the lower surface of collagen foil biomatrix illustrate the substantial non-porosity of the collagen foil biomatrix in Figure 3.
• this material is suitable for temporarily replacing the body's own tissue in closing and separating the defect after covering and provides a biofunctional biomatrix scaffold for cell in-growth for forming a new tissue.
• the multiple layer structure of the present invention enhances the liquid-tight characteristic of the collagen foil biomatrix.
• the collagen foil biomatrix is substantially non-porous, interstices exist between the layers of collagen fibrils.
• the collagen foil biomatrix is analogous to a stack of pages wherein each page is substantially smooth and non-porous, with a space between each page. When in its dry form the interstices are more pronounced. The interstices become reduced when the collagen foil biomatrix is observed under near natural conditions in a slightly humid atmosphere. The reduction of the interstices of the collagen foil biomatrix is illustrated in pictures of cross sections of collagen foil biomatrix in a humid atmosphere in Figure 5.
• the numerous parallel-oriented thin collagen fibril layers of the collagen foil biomatrix simultaneously serve as a bioequivalent biofunctional scaffold for cell in-growth for de novo construction of the body's own tissue.
• the change in volume of the collagen foil biomatrix used according to the present invention is small or negligible when hydrated.
• the collagen foil biomatrix substantially retains its size and shape upon being hydrated, having excellent shape stability even after hydration, and causing no problems of swelling or shrinking following the contact with the tissue.
• collagen foil biomatrix does not significantly expand or contract in area or thickness to the extent that it would tear surgical sutures or break apart fibrin or other biocompatible glue seals that hold the collagen foil biomatrix to the patient's tissue.
• the shrinking or swelling of the area of the dry collagen foil biomatrix may vary from about -5% to about 20% when completely hydrated.
• the area of the dry collagen foil biomatrix may vary between about -5% to about 10% when completely hydrated. In a further example, the area of the dry collagen foil biomatrix varies between about -5% to about 5% when completely hydrated. For example, the area of the dry collagen foil biomatrix increases no more than about 4 percent when completely hydrated.
• the collagen foil biomatrix increases up to about 6 times its dry thickness when it is completely hydrated. In another example, the collagen foil biomatrix increases up to about 3 times its dry thickness when it is completely hydrated. In another example, the collagen foil biomatrix increases to about twice its dry thickness when it is completely hydrated.
• the thickness of the collagen foil biomatrix for use in the present invention may vary as required by a particular application. Varying the amount of starting material utilized to produce a particular size of collagen foil biomatrix can control the thickness of the collagen foil biomatrix.
• the collagen foil biomatrix used according to the present invention when in its dry form, has a thickness between about 0.01 mm to about 3.0 mm.
• the collagen foil biomatrix has a thickness between about 0.02 mm to about 2.0 mm.
• the collagen foil biomatrix has a thickness between about 0.03 mm to about 1.5 mm.
• the collagen foil biomatrix has a thickness between about 0.05 mm to about 1 mm.
• the collagen foil biomatrix has a thickness of about 1.0 mm or less.
• the dry weight of the collagen foil biomatrix is dependent on its desired thickness. In one example, the dry weight of the collagen foil biomatrix is between about 1 mg/cm 2 to about 50 mg/cm 2 . In another example, the dry weight of the collagen foil biomatrix is between about 1.5 mg/cm 2 to about 30 mg/cm 2 . In still another example, the dry weight of the collagen foil biomatrix is between about 2 mg/cm 2 to about 20 mg/cm 2 . In a further example, the dry weight of the collagen foil biomatrix is between about 2.5 mg/cm 2 to about 15 mg/cm 2 . For example, the dry weight of the collagen foil biomatrix is between about 3 mg/cm 2 to about 10 mg/cm 2 .
• the weight of the collagen foil biomatrix increases up to about 15 times its dry weight upon hydration. In another example, the weight of the collagen foil biomatrix increases up to about 10 times its dry weight upon hydration. In another example, the weight of the collagen foil biomatrix increases up to about 7 times its dry weight upon hydration. In still another example, the weight of the collagen foil biomatrix increases up to about 5 times upon hydration from its dry state.
• the collagen foil biomatrix used according to the present invention beneficially has high tensile strength, which improves and supports the handling of the collagen foil biomatrix e.g. during its surgical application and provides an increased mechanical stability, e.g., after its implantation. Additionally, increasing the thickness of the collagen foil biomatrix can significantly increase the tensile strength.
• the propensity of collagen foil biomatrix material to tear under exerted pressure may be measured as its "ultimate tensile load” or “ultimate tensile force,” hereinafter referred to as “ultimate tensile force.”
• the ultimate tensile force of a collagen foil biomatrix may be determined by subjecting pressure to a strip of collagen foil biomatrix having a specified width and determining the amount of pressure applied that results in failure (e.g., tearing or rupturing) of the collagen foil biomatrix.
• the collagen foil biomatrix has an ultimate tensile force between about 1 and about 30 Newtons/cm-strip, for example between about 1.5 and about 15 Newtons/cm-strip, for example between about 2 and about 10 Newtons/cm-strip, for example between about 3 and about 6 Newtons/cm-strip.
• the collagen foil biomatrix used according to the present invention has a high tensile strength, it remains elastic and flexible when hydrated. This feature permits the collagen foil biomatrix to optimally adapt to the anatomic conditions (e.g. curves) present at the contact site.
• the collagen foil biomatrix When in its hydrated state, the collagen foil biomatrix can be easily moved around e.g. in the surgical site and optimally modeled and adapted to the shape and position of the defect e.g. where it is being implanted. Once implanted, the collagen foil biomatrix graft remains smooth and may be repositioned if necessary. Over time, cells and vasculature migrate directed throughout the multiple layers of the multilayered collagen foil biomatrix, eventually replacing the multilayered collagen foil biomatrix with a new tissue. As cells migrate and vasculature forms within the layers of the collagen foil biomatrix, the tissue takes on the form of the collagen foil biomatrix in a directed way. After cellular organization of the collagen foil biomatrix with the newly formed connective tissue, adhesion formation to the spinal dura or spinal nerve tissues is minimized.
• Collagen for use in manufacturing the collagen foil biomatrix may be obtained from any suitable source.
• collagen may be of bovine, ovine, porcine, equine, or human origin.
• the collagen may be harvested from a naturally occurring tissue, such as tendon, corium, or other collagen rich tissue or may be produced by recombinant genetic means.
• one exemplary embodiment of the invention utilizes equine collagen derived from Achilles tendon.
• the collagen fibrils become naturally cross-linked as the fibrils precipitate out of solution to form a collagen foil.
• chemicals or radiation e.g. ionizing or ultraviolet radiation
• allowing natural cross-linking of the collagen fibrils ensures their biofunctionality, promotes accelerated regeneration, and reduced resorption times once the collagen foil biomatrix is brought into contact with the tissue.
• Cross-linking collagen fibrils with chemicals or radiation can result in increased resorption times, or even non-resorption, encapsulation, and scar formation.
• the natural cross-linking of the fibrils in the collagen foil biomatrix utilized in the invention occurs by natural, physiological-like means.
• this natural cross-linking is through non-covalent interactions (e.g. van der Waals or dipole-dipole interactions) or by the formation of readily dissociable Schiff-base bonds between the amino acid side chains of the collagen molecule, lntermolecular cross-linking of collagen is responsible for physical and chemical stability.
• the fibrils of the product of the present invention may be dissociated by treatment with, for example, a weak acid.
• Cross-linking arising from the use of chemical cross-linking agents can be detected from the presence of stable covalently cross-linked cross-linking moieties. Commonly, this is accomplished by using a Schiff-base reagent (e.g. glutaraldehyde) to form Schiff-base reaction products, and then stabilizing the bonds through either an Amadori-rearrangement or reducing conditions.
• collagen can be cross-linked by various bifunctional carbodiimide reagents.
• Cross- linking arising from the use of radiation can be detected by the presence of stable covalent bonds between the collagen fibrils, caused by the reaction of free radical moieties generated during irradiation.
• the fibrils in the product of the present invention are substantially uncross-linked with any stable covalent bonds, and have not been treated in a chemical or irradiative manner.
• any associations between the fibrils in the product of the invention are substantially non-covalent or readily reversible, and are not stably cross-linked.
• Chemicals such as cyanamide, glutaraldehyde, formaldehyde, acrylamide, carbodiimidediones, diimidates, bisacrylamides, and the like have been utilized in the past to chemically cross-link collagen fibrils.
• Use of such chemicals may result in toxicity risks associated with inadvertently contacting neural tissue with residual chemicals in the collagen foil biomatrix.
• the precipitation process thereby avoids the toxicity risks of cross-linking chemicals and longer resorption times associated with cross-linking the collagen fibrils with chemicals or radiation.
• the resulting dried, precipitated, collagen composition forms an collagen foil biomatrix comprised of a high-molecular weight multi-layered collagen membrane consisting of numerous layers of two-dimensionally multi-directional naturally intertwined collagen fibrils.
• the collagen foil biomatrix primarily contains interstitial Type I collagen.
• the collagen foil biomatrix has substantially no pores and is primarily liquid-tight. Immune diffusion tests may be conducted on the product to guarantee the absence of foreign protein.
• the collagen foil biomatrix may be gas-sterilized with ethylene oxide (ETO) or similar sterilization gas or by irradiation.
• ETO ethylene oxide
• a significant benefit of using an equine collagen foil biomatrix according to the present invention is the substantially low risk of transmitting a disease to a patient being contacted with said foil.
• the manufacturing process in which the collagen fibrils are treated with acids (e.g. hydrochloric acid, acetic acid, and the like) and bases, such as sodium hydroxide, to produce the equine collagen foil beneficially acts to inactivate or reduce the infectious levels of bacteria, viruses, and prions that may be present.
• Treatment of biomaterial with hydrochloric acid, sodium hydroxide, ethylene oxide (ETO), and the like have been recognized in the prior art as approved methods within drug and biomaterial regulations to inactivate prions and viruses. Such treatment may, under some regulations, reduce the regulatory requirements for testing the equine collagen foil on a batch-by-batch basis.
• the treatment of the collagen fibrils during the manufacturing process enhances the product safety and reduces the risk of disease transmission to a patient.
• Equine material that has been subjected to the manufacturing process described above is not known to transmit any pathogens to patients.
• utilization of equine-based collagen further avoids the risks of transmitting spongiform encephalitis that have been previously associated with human cadaveric materials.
• the use of collagen derived from an equine origin, such as collagen derived from equine Achilles tendons avoids the risks of transmitting transmissible spongiform encephalopathy (TSE), which is also known as bovine spongiform encephalopathy (BSE) or scrapie. Transmission of this disease has been associated with the use of biological material obtained from ruminant sources (e.g. biological material from cattle, goats, sheep, and the like).
• the collagen foil biomatrix used according to the present invention wherein the collagen is derived from an equine origin and treated (e.g. with enzymes) additionally reduces the risk of eliciting an immune response.
• Equine-derived collagen foil biomatrix also results in a reduced inflammatory response.
• the number of inflammatory cells resulting from the contact with the equine collagen foil biomatrix is significantly lower.
• the dry collagen foil biomatrix may be hydrated, e.g. in physiological saline.
• the physiological saline comprises a 0.9% sodium chloride solution.
• the collagen foil biomatrix is hydrated in excipients or drug- containing solutions. The length of time necessary to hydrate the collagen foil biomatrix is related to the thickness of the foil. The collagen foil biomatrix is hydrated until it is consistent in thickness across its entire area. In one example the collagen foil biomatrix is hydrated between about 0.5 seconds and about 1 hour in physiological saline. In another example the collagen foil biomatrix is hydrated between about 0.5 seconds and about 30 minutes in physiological saline.
• the collagen foil biomatrix is hydrated between about 0.5 seconds and about 20 minutes in physiological saline. In another example the collagen foil biomatrix is hydrated between about 0.5 seconds and about 10 minutes in physiological saline. In still another example the collagen foil biomatrix is hydrated between about 0.5 seconds and about 2 minutes in physiological saline. In another example the collagen foil biomatrix is hydrated about 0.5 seconds to ten seconds in physiological saline, e.g., by dipping the collagen foil biomatrix into physiological saline. In another example the collagen foil biomatrix is not hydrated prior to contacting the tissue.
• the collagen foil biomatrix may be attached to the patient's tissue by established surgical techniques, e.g. by fibrin sealant, tissue glue, surgical sutures, or by pressure fitting surgical techniques.
• the natural attraction between the collagen foil biomatrix and the tissue, or the blood on the surface of the tissue can be used to attach the collagen foil biomatrix to the tissue without the use of any sealant, glue, sutures, or pressure fitting techniques.
• the collagen foil biomatrix can be cut slightly larger than e.g. the surgical opening in the patient's tissue.
• the collagen foil biomatrix thereby slightly overlaps the patient's tissue to which it is attached.
• the hydrated collagen foil biomatrix is sized to have an approximately 0.5 cm to about 1 cm overlap with the tissue. The amount of overlap can vary depending on the preferences and skill of the surgeon.
• the collagen foil biomatrix can be fixed in place with fibrin sealant.
• fibrin sealant approved for surgical use include TISSUCOL and TISSEEL fibrin sealants (Baxter AG, Vienna, Austria).
• a tissue glue that does not induce an extensive inflammatory reaction, and is approved for use in spinal surgery may also be utilized.
• the fibrin sealant or tissue glue may be applied in a continuous line around the portion of the collagen foil biomatrix that overlaps the tissue in order to form a liquid-tight seal.
• a liquid-tight seal fixation is advantageous as it avoids complications associated with contact of the adjacent tissues with hemorrhages, e.g., induction of adhesion formation by fibrin.
• the collagen foil biomatrix produces a liquid-tight seal when attached to the tissue with a continuous line of fibrin sealant or tissue glue.
• the collagen foil biomatrix that overlaps the tissue can be dotted with fibrin sealant or tissue glue to attach it to the tissue.
• the collagen foil biomatrix is attached by surgically suturing it to the tissue once it has been positioned to the desired contact site. If the collagen foil biomatrix is to be sutured, tensionless suturing techniques must be used to prevent tearing the foil.
• the collagen foil biomatrix is positioned and implanted according to pressure fitting techniques known in the art. In this technique, the collagen foil biomatrix is positioned in the desired implantation site and held in place by the surrounding tissues. Thus, the graft remains in place without the use of surgical sutures, fibrin sealant, or tissue glue. In another example, the collagen foil biomatrix is positioned and implanted without the use of any sealant, glue, sutures, or pressure fitting techniques. In this technique, the collagen foil biomatrix is positioned in the desired implantation site and held in place by the natural attraction or adhesion that occurs between the collagen foil biomatrix and the mammalian tissue.
• the collagen foil biomatrix may be applied to a tissue and affixed by any of the methods above, and then another collagen foil biomatrix may be applied to an adjacent tissue, and applied by any of the methods above, thus resulting in adjacent sheets of the collagen foil biomatrix.
• the collagen foil biomatrix of the present invention may be utilized in conjunction with other products.
• an ant-adhesion product may be applied to the upper or lower surface of the collagen foil biomatrix, or to adjacent tissues.
• a PEG based product such as CoSeal® (available from Baxter Healthcare corporation) may be applied to the upper or lower surface of the collagen foil biomatrix, or to adjacent tissues.
• collagen foil biomatrix of the invention prevents adhesion by separating tissues and by directing tissue regeneration, rather than by creating a "slippery” surface, its action may be complemented by utilizing products that temporarily create a "slippery” surface to which cells will not adhere.
• a ready-to-use collagen foil biomatrix which is already coated with a PEG-based product on one or both surfaces may be used.
• the present invention is related to the use of a multilayered collagen foil biomatrix in the manufacture of a medicament, i.e. a medically applicable material, for treating a disorder such as e.g. injuries, surgeries, or pathogen-based diseases, in a mammal characterized by a disconnection of a tissue selected from the group consisting of spinal column and dura mater, and the surrounding tissue.
• a medicament i.e. a medically applicable material
• -intraoperative measures for prevention and minimization of postoperative adhesions e.g. implantation of anti-adhesive implants like sponges, foils or gel.
• the surgical goal is the optimization of the surgical wound situation during and in the early postoperative period. It is known that wound conditions in this period are mainly responsible for the formation of any postoperative adhesion and fibrosis formation.
• the situation at two weeks post-operation allows the evaluation of the integration of the implant and conclusions of the kind and potential of the bioactivity, biofunctionality and tissue compatibility of implants.
• the implant well accepted, cellularized and integrated into the dorsal anatomy or, in contrast, does it act as a long term foreign body and provokes encapsulations and scar formation?
• the aim of the following Examples is to evaluate the biofunctionality as a temporary separation layer and as biomatrix for cell growth and tissue regeneration of a biological collagen foil biomatrix in the postoperative period and the value for the prevention and minimization of clinically relevant adhesion and uncontrolled scar tissue formation.
• Example I Materials and Methods: Animal Experiments showing reduced adhesions in spinal surgery using the biofunctional collagen foil biomatrix
• Group 2 Laminectomy, Covering with collagen foil biomatrix.
• the animals were positioned in a prone position and secured with the surgical area (lumbar spine) shaved. Under sterile conditions, after median incision of the skin, the Para vertebral musculature was detached from the spinous processes and the laminae of the lumbar vertebral spinal column exposed. Hemilaminectomy of the 3 rd and 4 th lumbar vertebra was conducted. Exposure of the two corresponding spinal nerve roots and of the root channels. Continuation of surgery in accordance with the different groups is also described.
• Pain medication 2 x day. Temgesic 0,05mg/kg s.c. for 3-4 days post operative.
• Example II Collagen foil biomatrix one week after implantation in human patient
• the human patient (age: 18, gender: female) was operated in the interval of 7 days in the frame of a routine surgical treatment (epilepsy).
• the collagen foil biomatrix was implanted epidural during the first surgery (prevention of CSF leaks).
• the collagen foil biomatrix implant was removed routinely before the reopening of the dura.
• the collagen foil biomatrix is still mechanically stable and removable as shown in Fig.10.
• Fig. 11 is a sectional view of the collagen foil biomatrix of Figure 10 one week after implantation. As can be seen, fibroblasts are growing into the collagen foil biomatrix, directed by the multi-layer structure. The penetration in longitudinal direction is about 220 to 320 ⁇ m.
• the speed of the directed in-growth of repair cells along the multi-layered structure is about 10 to 15 times higher in longitudinal direction compared to the transversal direction (,,Fig. 10"). Minimal inflammatory infiltration is shown, expressing the ongoing regenerative process.
• Example III Cell growth, tissue regeneration and prevention of peridural adhesion and fibrosis after implantation of a collagen foil biomatrix in spinal surgery
• Native equine collagen fibrils (mainly type I collagen) produced from purified minced Achilles tendon from horses and precipitated to fibrils.
• the flexible formstable and elastic biomatrix is specially engineered and has a nonporous fluid tight multilayer structure.
• the thickness of the dry equine multilayered collagen foil membrane was about 0.1 mm. In the wet condition the membrane thickness growth up to 0.3 mm.
• Pain medication 2 x day. Temgesic 0,05mg/kg s.c. for 3-4 days post operative.
• the present study was performed on New Zealand White (“NZW”) rabbits weighing on average 3 kg at the time of surgery and their average age was 4 months. All rabbits were female and approval for the animal studies were performed after formal approval by the authorities of the city of Vienna, Austria.
• the design of surgery in this experimental animal model in rabbits was similar to the most common operative intervention in humans.
• a laminectomy and resection was performed of the facet joint at the lumbar spine 4 to 5 (L4/5).
• PLIF Posterior Lumbar Interbody Fusion
• the ligamentum flavum was resected.
• the dura above the spinal cord remained intact.
• the laminectomy area was covered by a biological collagen foil biomatrix of the present invention.
• the paravertebral muscle was moved back in place and the fascia was closed by absorbable sutures.
• the skin was closed using syntofil sutures.
• the rabbits received postoperative pain medication and fluid infusion during the first three days and received mixed food.
• the rabbits were euthanized by overdose of thiopental and the operated areas of the spine were removed and isolated for histological evaluation.
• the vertebral column was excised en bloc and immersed in 10% formalin solution for fixation. After decalcification each lumbar vertebra was cut into slices, dehydrated and embedded in paraffin. Seven sections 3 ⁇ m thick were taken from each sample.
• the sections were stained with Haematoxilin-Eosin for general histology staining all cells and bone components
• the slides were examined by evaluating anatomical structures like relation between dura mater and the peridural dorsal surgical wound area, cell in-growth into the collagen foil biomatrix and the absence/presence and extent of adhesion formation and peridural fibrous scar formation.
• the sections were stained with Haematoxilin-Eosin for general histology staining all cells and bone components
• the slides were examined by evaluating anatomical structures like relation between dura mater and the peridural dorsal surgical wound area.
• Cell growth into and on the collagen foil biomatrix and the quantity and quality of the inflammatory reaction in the biomatrix and surrounding tissue were analyzed.
• the integration/incorporation process and the absence/presence and extent of adhesion formation and peridural connective tissue organization were also analyzed.
• the collagen foil biomatrix is placed between the dura mater and the dorsal defect area and forms a biological separation layer between the dura mater and the dorsal wound area. It is not fixed to the tissue of the dorsal defect. Blood (erythrocytes) adhere in a thin layer to the surface of the collagen foil biomatrix and proves its function as a hemostat.
• Blood erythrocytes
• the parallel microscopically multilayer structure of the collagen foil biomatrix which is nonporous and fluid-tight to blood, is clearly visible.
• the thickness of the collagen foil biomatrix is about 0.3 mm. (Fig. 12)
• the membrane is mostly integrated in the surrounding tissues. There is infiltration of blood cells, especially lymphocytes (Fig 13 A).
• the subdural space is free from cell infiltration or adhesion tissue.
• On the dorsal surface cells are directed along the surface and have hardly penetrated the surface of the collagen foil biomatrix. At the edges of the defect the collagen biomatrix was applied on the bone.
• the contact area (a) is a preferred area of bioactivity (biomatrix / cell interaction) and the beginning of directed cell infiltration along the multilayer structure.
• the area between the multilayered collagen foil biomatrix and the dura mater consists of loose tissue containing fat cells (b), comparable to the tissue of the epidural space in areas where the anatomy was not affected by the surgery (c) as shown in Fig. 13 A.
• Fig. 13 A shows the contact area between the multilayered collagen foil biomatrix and the bone at the edge of the defect (a).
• the remodelling of the multilayered collagen foil biomatrix starts with the directed infiltration of cells (fibroblasts, granulocytes) into the parallel multilayer structure of the multilayered collagen foil biomatrix.
• Fig. 13 B shows the contact area between the multilayered collagen foil biomatrix and the bone at the edge of the defect (a).
• Fig. 13 C shows the multilayered collagen foil biomatrix in the center of the laminectomy defect.
• the collagen biomatrix is integrated and is separating the ventral epidural space from the dorsal scar formation. Cells are directed along the dorsal surface and have not penetrated the surface of the collagen biomatrix.
• the area between the collagen biomatrix and the dura mater consists of loose tissue containing fat cells (a).
• FIG. 13 D shows a NZW rabbit 1 week postoperative.
• the multilayered collagen foil biomatrix is closing the laminectomy defect and separating the dura from the beginning cell rich dorsal scar formation. Cells have not penetrated the surface of the collagen biomatrix. At the edge of the collagen biomatrix the beginning of directed infiltration of repair cells into the multilayer structure(a) is seen.
• Fig. 13 E shows a NZW rabbit 1 week postoperative.
• a collagen sponge (DURAGEN) was used to cover the laminectomy defect.
• the collagen sponge is soaked with blood.
• the integration of the membrane into surrounding tissue is improved by in-growth of capillaries structures.
• the amount of the lymphocyte, segmented granulocyte is increased.
• the structure of the collagen foil biomatrix can be distinguished form the surrounding tissue.
• the subdural space is free from cell infiltration or adhesion tissue.
• Figs. 14 A - C show a NZW rabbit two weeks postoperative.
• the multilayered collagen foil biomatrix is fully integrated.
• Tissue repair cells have infiltrated the collagen biomatrix and are directed along the multilayer structure.
• the dura mater is separated by loose tissue with fat cells from the scar formation and the remodelled collagen biomatrix.
• the nonporous multilayered collagen foil biomatrix of the present invention proved to have an immediate and excellent separation and protection function between the dura mater and the dorsal surgical defect, avoiding the uncontrolled distribution of blood, fibrin and necrotic materials into the peridural area and directing and separating the cell growth of the beginning scar above the dorsal surface.
• the biofunctional collagen foil also directs the cell in-growth into its multilayer structure. The speed of ingrowth along the multilayered structure is higher than the in-growth of cells into the biomatrix from the dorsal surface. There is no in-growth of cells in the first week into the ventral surface of the collagen foil biomatrix. The different speed of cell in-growth along or across the multilayered structure is in line with a clinical observation after the peridural implantation of the multilayered collagen foil biomatrix one week postoperative (Ex. II).
• the multilayered biomatrix is infiltrated by repair cells.
• repair cells There is a full integration of the biomatrix into the physiological scar formation of the dorsal surgical wound area.
• the dura mater is separated by a loose fat tissue which looks similar to the fat tissue, which is physiologically separating the dura mater from the spinal canal.
• the biomatrix is remodeled and integrated into the normal anatomical structure.
• the multilayered collagen foil biomatrix of the present invention proved to be an effective, biocompatible and biofunctional immediate protection and separation layer between the dura mater and the dorsal defect area which is directing the cell in-growth within the multilayer structure and the cell growth above its dorsal surface.
• the collagen foil biomatrix effectively controls the remodeling and tissue regeneration process and provides optimal conditions for the prevention and minimization of clinically relevant adhesions.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Vascular Medicine (AREA)
• Heart & Thoracic Surgery (AREA)
• Surgery (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Transplantation (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Biomedical Technology (AREA)
• Cardiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Materials For Medical Uses (AREA)
• Prostheses (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Publications (3)

Family

ID=38457907

Family Applications (1)

Country Status (13)

Cited By (26)

Families Citing this family (11)

Citations (2)

Family Cites Families (131)

• 2007
  • 2007-05-30 MX MX2008014847A patent/MX2008014847A/es active IP Right Grant
  • 2007-05-30 WO PCT/EP2007/004791 patent/WO2007137839A2/en not_active Ceased
  • 2007-05-30 CN CN200780019553XA patent/CN101454030B/zh active Active
  • 2007-05-30 BR BRPI0712088A patent/BRPI0712088B8/pt not_active IP Right Cessation
  • 2007-05-30 CA CA2651941A patent/CA2651941C/en active Active
  • 2007-05-30 AU AU2007267338A patent/AU2007267338B2/en not_active Ceased
  • 2007-05-30 ES ES07725680.8T patent/ES2575933T3/es active Active
  • 2007-05-30 JP JP2009512489A patent/JP5231401B2/ja not_active Expired - Fee Related
  • 2007-05-30 EP EP07725680.8A patent/EP2021045B1/en active Active
  • 2007-05-30 US US12/302,716 patent/US8703122B2/en active Active
  • 2007-05-30 KR KR1020087031934A patent/KR20090017654A/ko not_active Ceased
• 2008
  • 2008-12-29 CO CO08137571A patent/CO6140041A2/es unknown
  • 2008-12-30 NO NO20085419A patent/NO20085419L/no not_active Application Discontinuation

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events